G Cameron 2017 Pharmacy Law Update Husson University April 1 2017 Greg Cameron RPh NO APRIL FOOLS 1 2017 Maine Pharmacy Association Spring Convention G Cameron 2017 Dental Hygienists and Fluoride Dispensing ID: 742714
Download Presentation The PPT/PDF document "2017 Maine Pharmacy Association Spring C..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
Pharmacy Law UpdateHusson UniversityApril 1, 2017Greg Cameron, R.Ph(NO APRIL FOOLS)
1Slide2
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
Dental Hygienists and Fluoride DispensingOpioid Law and Regulations Update
Drug Quality and Security Act 2013
Comprehensive Addiction & Recovery Act 2016
Technician & Intern Duties
Recent Board of Pharmacy Actions
OBJECTIVES
2Slide3
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
Public Law 114–198, 114th CongressComprehensive Addiction and Recovery Act of 2016
(
696 PAGES
)
REASON:To authorize the Attorney General and Secretary of Health and Human
Services to award grants to address the prescription opioid abuse and heroin use crisis, and
for other
purposes
Comprehensive Addiction and Recovery Act of 2016
3Slide4
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
Parts of this LAW:TITLE I—PREVENTION AND EDUCATION
TITLE
II—LAW ENFORCEMENT AND
TREATMENT
TITLE III—TREATMENT AND RECOVERY
TITLE IV—ADDRESSING COLLATERAL CONSEQUENCES
TITLE
V—ADDICTION AND TREATMENT SERVICES FOR WOMEN, FAMILIES
, AND VETERANS
TITLE
VI—INCENTIVIZING STATE COMPREHENSIVE INITIATIVES TO ADDRESS PRESCRIPTION OPIOID
ABUSE
TITLE VII—MISCELLANEOUS
Sec
. 702. Partial fills of schedule II controlled substances
Comprehensive Addiction and Recovery Act of 2016
4Slide5
SEC. 702. PARTIAL FILLS OF SCHEDULE II CONTROLLED SUBSTANCES
Partial Fills - A prescription for a controlled substance in schedule II may be partially filled if—
it is not prohibited by State lawthe prescription is written and filled in accordance with this title, regulations prescribed by the Attorney General, and State lawthe partial fill is requested by the patient or the practitioner that wrote the prescription; and the total quantity dispensed in all partial fillings does not exceed the total quantity prescribed
Comprehensive Addiction and Recovery Act of 2016
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
5Slide6
SEC. 702. PARTIAL FILLS OF SCHEDULE II CONTROLLED SUBSTANCES
REMAINING PORTIONS.— IN GENERAL.—Except as provided in subparagraph (B), remaining portions of a partially filled prescription for a controlled substance in schedule II—
may be filled; and shall be filled not later than 30 days after the date on which the prescription is writtenEMERGENCY SITUATIONS.—In emergency situations, the remaining portions of a partially filled prescription for a controlled substance in schedule II—
may be filled; and
shall be filled not later than 72 hours after the prescription is issued
2017 Maine Pharmacy Association Spring Convention
Comprehensive Addiction and Recovery Act of 2016
G. Cameron 2017
6Slide7
SEC. 702. PARTIAL FILLS OF SCHEDULE II CONTROLLED SUBSTANCES
CURRENTLY LAWFUL PARTIAL FILLS.—Notwithstanding paragraph (1) or (2), in any circumstance in which, as of the day before the date of enactment of this subsection,
a prescription for a controlled substance in schedule II may be lawfully partially filled, the Attorney General may allow such a prescription to be partially filled
2017 Maine Pharmacy Association Spring Convention
Comprehensive Addiction and Recovery Act of 2016
G. Cameron 2017
7Slide8
SEC. 702. PARTIAL FILLS OF SCHEDULE II CONTROLLED SUBSTANCES
RULE OF CONSTRUCTION.—Nothing in this section shall be construed to affect the authority of the Attorney General to allow a prescription for a controlled substance in schedule III, IV, or V of section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) to be partially filled
2017 Maine Pharmacy Association Spring Convention
Comprehensive Addiction and Recovery Act of 2016
G. Cameron 2017
8Slide9
Compounding Quality Act
Title I of the Drug Quality and Security Act of 2013
On November 27, 2013, President Obama signed the Drug Quality and Security Act (DQSA), legislation that contains important provisions relating to the oversight of compounding of human drugs.
G. Cameron 2017
Drug Quality and Security Act of
2013 (Compounding Quality Act)
9
2017 Maine Pharmacy Association Spring ConventionSlide10
H.R.3204 — 113th Congress (2013-2014)
Public Law No: 113-54 (11/27/2013)
Drug Quality and Security Act - Title I: Drug Compounding - Compounding Quality Act(Sec. 102) Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) with respect to the regulation of compounding drugs
G. Cameron 2017
10
2017 Maine Pharmacy Association Spring Convention
Drug Quality and Security Act of
2013 (Compounding Quality Act)Slide11
Exempts compounded drugs from:
new drug requirements
labeling requirementstrack and trace requirementsIF, the drug is compounded by or under the direct supervision of a licensed pharmacist in a registered outsourcing facility and meets applicable requirements
G. Cameron 2017
11
2017 Maine Pharmacy Association Spring Convention
Drug Quality and Security Act of
2013 (Compounding Quality Act)Slide12
Establishes annual registration requirement for any
outsourcing facility
Requires a facility to report biannually to the Secretary of Health and Human Services (HHS) on what drugs are compounded in the facility and to submit adverse event reportsSubjects such facilities to a risk-based inspection schedule
G. Cameron 2017
12
2017 Maine Pharmacy Association Spring Convention
Drug Quality and Security Act of
2013 (Compounding Quality Act)Slide13
Requires the Secretary to:
Assess an annual establishment fee on each outsourcing facility
A re-inspection fee, as necessary
G. Cameron 2017
13
2017 Maine Pharmacy Association Spring Convention
Drug Quality and Security Act of
2013 (Compounding Quality Act)Slide14
Prohibits the resale of a compounded drug labeled “not for resale” or the intentional falsification of a prescription for a compounded drug
Deems a compounded drug to be misbranded if its advertising or promotion is false or misleading
G. Cameron 2017
14
2017 Maine Pharmacy Association Spring Convention
Drug Quality and Security Act of
2013 (Compounding Quality Act)Slide15
State Boards of Pharmacy are required to send reports:
Describing any disciplinary actions taken against compounding pharmacies
Any recall of a compounded drugAny concerns that a compounding pharmacy may be violating the FFDCA
G. Cameron 2017
15
2017 Maine Pharmacy Association Spring Convention
Drug Quality and Security Act of
2013 (Compounding Quality Act)Slide16
Revises compounding pharmacy requirements:
Repeals prohibitions on advertising and promotion of compounded drugs
Repeals the requirement that prescriptions filled by a compounding pharmacy be unsolicited
G. Cameron 2017
16
2017 Maine Pharmacy Association Spring Convention
Drug Quality and Security Act of
2013 (Compounding Quality Act)Slide17
LABELING OF DRUGS.
LABEL.—The label of the drug includes—
the statement ‘This is a compounded drug.’ or a reasonable comparable alternative statement (as specified by the Secretary) that prominently identifies the drug as a compounded drugthe name, address, and phone number of the applicable outsourcing facility
G. Cameron 2017
17
2017 Maine Pharmacy Association Spring Convention
Drug Quality and Security Act of
2013 (Compounding Quality Act)Slide18
LABELING OF DRUGS.
LABEL.—The label of the drug includes—
with respect to the drug—the lot or batch number;the established name of the drug
the dosage form and strength
the statement of quantity or volume, as appropriate
the date that the drug was compounded
the expiration date
G. Cameron 2017
18
2017 Maine Pharmacy Association Spring Convention
Drug Quality and Security Act of
2013 (Compounding Quality Act)Slide19
LABELING OF DRUGS.
LABEL.—The label of the drug includes—
with respect to the drug— (CONTINUED)storage and handling instructions
the National Drug Code number, if available
the statement ‘Not for resale’, and
if the drug is dispensed or distributed other than pursuant to a prescription for an individual identified patient, the statement ‘Office Use Only’
a list of active and inactive ingredients, identified by established name and the quantity or proportion of each ingredient. (If it doesn’t fit on the label , see container requirement).
G. Cameron 2017
19
2017 Maine Pharmacy Association Spring Convention
Drug Quality and Security Act of
2013 (Compounding Quality Act)Slide20
Labeling of the
CONTAINER
—The container from which the individual units of the drug are removed for dispensing or for administration (such as a plastic bag containing individual product syringes) shall include—a list of active and inactive ingredients, identified by established name and the quantity or proportion of each ingredientinformation to facilitate adverse event reporting:
www.fda.gov/medwatch and 1–800– FDA–1088
directions for use, including, as appropriate, dosage and administration
G. Cameron 2017
20
2017 Maine Pharmacy Association Spring Convention
Drug Quality and Security Act of
2013 (Compounding Quality Act)Slide21
REGISTRATION OF OUTSOURCING FACILITIES
ANNUAL REGISTRATION
Upon electing and in order to become an outsourcing facility, shall register with the Secretary its name, place of business, a point contact email address, and unique facility identifiershall indicate whether the outsourcing facility intends to compound a drug that appears on the list in effect under section 506E during the subsequent calendar year
G. Cameron 2017
21
2017 Maine Pharmacy Association Spring Convention
Drug Quality and Security Act of
2013 (Compounding Quality Act)Slide22
REGISTRATION OF OUTSOURCING FACILITIES
AVAILABILITY OF REGISTRATION FOR INSPECTION LIST
The Secretary shall make available for inspection, to any person so requesting, any registration filed or facility registered as an outsourcing facilityState in which each such facility is located
whether the facility compounds from bulk drug substances, and
whether any such compounding from bulk drug substances is for sterile or non-sterile drugs
G. Cameron 2017
22
2017 Maine Pharmacy Association Spring Convention
Drug Quality and Security Act of
2013 (Compounding Quality Act)Slide23
REGISTRATION OF OUTSOURCING FACILITIES (Continued)
DRUG REPORTING BY OUTSOURCING FACILITIES
Report due once during the month of June, and once during the month of December of each yearidentifying the drugs compounded during the previous 6-month period and
with respect to each drug identified providing the active ingredient, the source of such active ingredient, the NDC of the source drug or bulk active ingredient, if available, the strength of the active ingredient per unit, the dosage form and route of administration, the package description, the number of individual units produced, and the National Drug Code number of the final product, if assigned
G. Cameron 2017
23
2017 Maine Pharmacy Association Spring Convention
Drug Quality and Security Act of
2013 (Compounding Quality Act)Slide24
REGISTRATION OF OUTSOURCING FACILITIES
RISK-BASED INSPECTION FREQUENCY
Outsourcing facilitiesshall be subject to inspectionRISK-BASED SCHEDULE.—The Secretary, acting through one or more officers or employees duly designated shall inspect outsourcing facilities in accordance with a risk-based schedule established by the Secretary’
24
G. Cameron 2017
2017 Maine Pharmacy Association Spring Convention
Drug Quality and Security Act of
2013 (Compounding Quality Act)Slide25
REGISTRATION OF OUTSOURCING FACILITIES
RISK FACTORS.—shall inspect outsourcing facilities according to the known safety risks of such outsourcing facilities, which shall be based on the following factors
The compliance history of the outsourcing facilityThe record, history, and nature of recalls linked to the outsourcing facility
The inherent risk of the drugs compounded at the outsourcing facility
The inspection frequency and history of the outsourcing facility
Whether the outsourcing facility has registered
G. Cameron 2017
25
2017 Maine Pharmacy Association Spring Convention
Drug Quality and Security Act of
2013 (Compounding Quality Act)Slide26
REGISTRATION OF OUTSOURCING FACILITIES
ADVERSE EVENT REPORTING.—Outsourcing facilities shall submit adverse event reports to the Secretary
INTERIM LIST.— the Secretary may designate drugs, categories of drugs, or conditionsUPDATES.—The Secretary shall review, and update as necessary, the regulations containing the lists of drugs, categories of drugs, or conditions regularly, but not less than once every 4 years
G. Cameron 2017
26
2017 Maine Pharmacy Association Spring Convention
Drug Quality and Security Act of
2013 (Compounding Quality Act)Slide27
REGISTRATION OF OUTSOURCING FACILITIES
DEFINITIONS
The term ‘compounding’ includes the combining, admixing, mixing, diluting, pooling, reconstituting, or otherwise altering of a drug or bulk drug substance to create a drugG. Cameron 2017
27
2017 Maine Pharmacy Association Spring Convention
Drug Quality and Security Act of
2013 (Compounding Quality Act)Slide28
REGISTRATION OF OUTSOURCING FACILITIES
DEFINITIONS
The term ‘essentially a copy of an approved drug’ meansa drug that is identical or nearly identical to an approved drug, or a marketed drug
a drug, a component of which is a bulk drug substance that is a component of an approved drug or a marketed drug, unless there is a change that produces for an individual patient a clinical difference, as determined by the prescribing practitioner, between the compounded drug and the comparable approved drug
G. Cameron 2017
28
2017 Maine Pharmacy Association Spring Convention
Drug Quality and Security Act of
2013 (Compounding Quality Act)Slide29
REGISTRATION OF OUTSOURCING FACILITIES
DEFINITIONS
The term ‘approved drug’ means a drug that is approved and does not appear on the list of drugs that have been withdrawn or removed from the market because such drugs or components of such drugs have been found to be unsafe or not effective
G. Cameron 2017
29
2017 Maine Pharmacy Association Spring Convention
Drug Quality and Security Act of
2013 (Compounding Quality Act)Slide30
REGISTRATION OF OUTSOURCING FACILITIES
DEFINITIONS
The term ‘outsourcing facility’ means a facility at one geographic location or address that—is engaged in the compounding of sterile drugshas elected to register as an outsourcing facility and
complies with all of the requirements of this section
is not required to be a licensed pharmacy
may or may not obtain prescriptions for identified individual patients
G. Cameron 2017
30
2017 Maine Pharmacy Association Spring Convention
Drug Quality and Security Act of
2013 (Compounding Quality Act)Slide31
REGISTRATION OF OUTSOURCING FACILITIES
DEFINITIONS
The term ‘sterile drug’ means a drug that is intended for parenteral administration, an ophthalmic or oral inhalation drug in aqueous format, or a drug that is required to be sterile under Federal or State law.’’
G. Cameron 2017
31
2017 Maine Pharmacy Association Spring Convention
Drug Quality and Security Act of
2013 (Compounding Quality Act)Slide32
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
32Slide33
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
An Act To Allow Dental Hygienists To Prescribe Fluoride Dentifrice And Antibacterial RinseApply topical antimicrobials, excluding antibiotics, including fluoride, for the purposes of bacterial reduction, caries control and desensitization in the oral cavity
The independent practice dental hygienist shall follow current manufacturer’s instructions in the use of these medicaments
33
Dental HygienistsSlide34
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
Prescribe, dispense, or administer anticavity toothpastes or topical gels with 1.1% or LESS sodium fluoride and oral rinses with 0.05%, 0.2%, 0.44%, or 0.5% sodium fluoride and:Prescribe, dispense, or administer chlorhexidine
gluconate
oral rinse
34
Dental HygienistsSlide35
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
35Opiate Law Update LD 1646
Effective 7/1/2017
Total MMEs are not to exceed 100mg /
day unless an exception
Pharmacists may dispense a lesser quantity than is
prescribed if requested by the patient
Pharmacist must notify the prescriber within 7 days
Remaining quantity is void (different then new Federal Law)
All opioid medications must be prescribed electronically, or prescribers must request a waiver from
DHHSSlide36
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
36Opiate Law Update LD 1646
PMP for the pharmacists (when to check)
Applies to Opioids and Benzodiazepines
Patient is not a Maine Resident
Rx is written by an out of state prescriber
Patient has not received a prescription for Opioids or Benzodiazepine within the previous 12 months
Patient pays cash when the actually have insurance
Pharmacists may be fined $250 per violation / $5,000 per year for failure to report to the PMPSlide37
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
37Opiate Law Update LD 1646
PMP Dispensers Must Review:
# of pharmacies filling controlled substances for this patient
# of prescribers prescribing controlled substances for this patient
Aggregate MME
Notify the PMP Office Coordinator and decline filling the prescription until you can contact the prescriber if you suspect the prescription is fraudulent or may be duplication of therapySlide38
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
38Opiate Law Update LD 1646
Days Supply
Indication of acute pain
7 days
Indication of chronic pain
30 days
Early RefillsSlide39
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
39Opiate Law Update LD 1646
Regulations
Definitions
Acute Pain
–
pain that is the normal, predicted physiological response to noxious chemical, thermal, or mechanical stimulus. This pain is typically associated with invasive procedures, trauma, and disease and is usually time-limited
Chronic Pain
–
pain that persists beyond the usual course of an acute disease or healing and may not be associated with an acute or chronic pathologic process that causes continuous or intermittent pain over months or yearsSlide40
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
40Opiate Law Update LD 1646
Code
Exemption
A
Pain associated with active and aftercare cancer treatment. Providers must document in the medical record that pain is directly related to cancer or cancer treatment. An exemption for aftercare may be claimed up to 6 months post-remission
B
Palliative care in conjunction with serious illness
C
End-of-life and hospice care
D
Medication assisted treatment
for SUD
E
Pregnant individual with pre-existing prescription for >100MMEs
(only applies during pregnancy
F
Acute pain for the patient with pre-existing opioid prescription for chronic pain. The acute pain must be new or onset or postoperative, 7day limit applies
G
Individuals pursuing an active taper of opioid medications with a maximum taper period of 6 months after which the opioid limitations
will apply unless the patient meets additional exceptionsSlide41
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
41Opiate Law Update LD 1646
Diagnosis
code:
ICD-10
code must be included on any (aggregate) prescription that exceeds 100 MMEs
Not required on veterinary prescriptions
Exemption code:
Must
be included if claiming exemption from the 100 MME aggregate daily limitSlide42
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
42Opiate Law Update LD 1646
Requirement that Dispensers Report Information to the PMP by Electronic
Means
No
later than the close of business on the next business day after dispensing a controlled substance, dispensers must report:
Dispenser identification numberDates prescription was filled and delivered (issued)Prescription number
Whether the prescription is new or a refill
National drug code (NDC) of the drug dispensed
Quantity
dispensed, Dosage
Patient ID number, name, address, and date of birthDate prescription was issued by the prescriberExemption code and ICD-10 code if aggregate >100 MMEs
If prescription is for animal
useSlide43
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
43Opiate Law Update LD 1646
https://
www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf
Calculating
Total Daily Dose of Opioids For Safer Dosage -
CDChttp://www.agencymeddirectors.wa.gov/Calculator/DoseCalculator.htm
Opioid Comparison TableSlide44
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
44Pharmacy Technicians & Pharmacy Interns
§13834. Prohibited acts
1.
Delegate authority.
A pharmacist may not delegate the pharmacist's authority to administer drugs or vaccines; except that a pharmacist licensed under this chapter who has obtained a certificate of administration pursuant to section 13832
may delegate the authority to administer drugs and vaccines to a pharmacy intern who is under that pharmacist's direct supervision and who has obtained drug administration training
pursuant to section 13832, subsection 3. A pharmacy intern may administer drugs and vaccines only
to a person 18 years of age or older
. [ 2013, c. 98, §1 (AMD) .]Slide45
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
45Pharmacy Technicians & Pharmacy Interns
Pharmacy Technicians
- A
pharmacy technician or pharmacy intern working under the direct supervision of a pharmacist
may:
Accept
delivery of prescription medication to be loaded into a dispensing machine at a point of care
location
Stock
a dispensing machine at a point of care
location
Remove
drugs from a dispensing machine at a point of care location for quality assurance purposes or to carry out a change in formulary;
and
Perform
other functions related to an automated pharmacy system except for
the removal of drugs from a dispensing machine at a point of care location for purposes of administration or dispensing to
patients.Slide46
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
46Pharmacy Technicians & Pharmacy Interns
No
person with access to a dispensing machine may remove more drugs than necessary to fill a prescription or meet the immediate needs of a patient in a hospital or
institution.Slide47
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
47Pharmacy Technicians & Pharmacy Interns
Telephone
Prescription Drug
Orders
A
pharmacist or
pharmacy intern may accept an original or renewal prescription drug order telephoned to a pharmacy by a practitioner or authorized agent of the
practitioner
A
pharmacy technician may accept an original or renewal prescription drug order telephoned to a pharmacy by a practitioner or authorized agent of the practitioner to the extent authorized by the pharmacist on
duty.
Facsimile
Prescription Drug
Orders
A
pharmacist, pharmacy intern or pharmacy technician
may accept a prescription drug order transmitted by facsimile machine or facsimile computer software directly to a pharmacy. Slide48
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
48Pharmacy Technicians & Pharmacy Interns
Generally
The
pharmacist in charge or the pharmacy shall determine the duties of pharmacy technicians based upon the needs of the
pharmacy
Pharmacy
technicians are limited to performing tasks in the dispensing of prescription legend drugs and nonjudgmental support
services
Automated
Pharmacy
Systems
A
pharmacy technician on duty at an institutional
pharmacy may
perform the duties relating to an automated pharmacy system
under
the direct supervision of a
pharmacistSlide49
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
49Pharmacy Technicians & Pharmacy Interns
Limitations
A
pharmacy technician may not perform any of the following
tasks:
Clinically
evaluate a patient profile relative to drugs that have or will be
dispensed;
Perform
patient
counseling;
Make
decisions that require the education and professional training of a pharmacist;
or
Sign
any federally-required controlled substance or inventory
formSlide50
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
50Pharmacy Technicians & Pharmacy Interns
Verification
of
Status
The
pharmacist in charge
shall ensure that each pharmacy technician employed at the pharmacy for which the pharmacist in charge is responsible is licensed with the
board
A
pharmacy technician shall carry the wallet-sized license card
issued by the board at all times the technician is on duty and shall produce the card upon request of the pharmacist in charge, a pharmacist on duty or an agent of the
board
No
pharmacist in charge or pharmacist on duty
shall permit a person who is not licensed
pursuant to the terms of this chapter to perform the duties of a pharmacy
technicianSlide51
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
51Pharmacy Technicians & Pharmacy Interns
Notice
of Employment and Non-Employment of Pharmacy
Technicians
The
pharmacist in charge shall notify the board via letter, fax, email or on line
within 10 days after the commencement or cessation of employment
of any pharmacy technician at a pharmacy for which the pharmacist in charge is
responsibleSlide52
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
52Pharmacy Technicians & Pharmacy Interns
Notice
of Termination of Employment For Drug-Related Reasons or
Theft
The
pharmacist in charge or a designee of the pharmacist in charge shall notify the board via letter, fax, email or on line of the termination of employment of a pharmacy technician for any of the following reasons and shall include in the notice the reason for the termination. Notice shall be provided
within 7 days after the
termination
Any
drug-related reason, including but not limited to adulteration, abuse, theft or
diversion;
Theft
of non-drug merchandise;
or
Theft
of cash or credit/debit card data
.Slide53
2017 Maine Pharmacy Association Spring Convention
G. Cameron 2017
53Pharmacy Technicians & Pharmacy Interns
Discipline
Pharmacy
technicians are subject to the disciplinary provisions of 10 MRSA §8003(5-A), 32 MRSA §§ 13742-A and 13743 and Chapters 30, 31 and 32 of the board's rules.